Saurabh Mehandru, MD

In this segment the panelists, Dr. Samir Parekh and Dr. Saurabh Mehandru, of Mount Sinai in New York, look ahead and close the discussion.

In this segment the panelists, Dr. Samir Parekh and Dr. Saurabh Mehandru, of Mount Sinai in New York, take up a second case.

In this segment the panelists, Dr. Samir Parekh and Dr. Saurabh Mehandru, of Mount Sinai in New York, work through a patient case.

In this segment the panelists, Dr. Samir Parekh and Dr. Saurabh Mehandru, both of Mount Sinai in New York, examine what drives immune effector cell-associated enteritis/colitis (IEC-EC) after chimeric antigen receptor (CAR) T-cell therapy and how to separate it from a malignant process. Dr. Mehandru describes two patterns.

In this segment the panelists, Dr. Samir Parekh and Dr. Saurabh Mehandru, of Mount Sinai in New York, discuss how severity is judged once endoscopy and histology have confirmed immune effector cell-associated enteritis/colitis (IEC-EC) after chimeric antigen receptor (CAR) T-cell therapy, and how that judgment shapes management.

In this segment the panelists, Dr. Samir Parekh and Dr. Saurabh Mehandru, of Mount Sinai in New York, work through the diagnostic approach to persistent diarrhea after chimeric antigen receptor (CAR) T-cell therapy for relapsed multiple myeloma.

In this segment the panelists, Dr. Samir Parekh and Dr. Saurabh Mehandru, both of Mount Sinai in New York, open their discussion of gastrointestinal toxicity following anti-B-cell maturation antigen chimeric antigen receptor (CAR) T-cell therapy for relapsed multiple myeloma.